Sequenom (SQNM) +3.9% premarket on news its subsidiary has completed several international...
Sequenom (SQNM) +3.9% premarket on news its subsidiary has completed several international distribution agreements that will expand access to the MaterniT21 PLUS testing service outside the U.S. MaterniT21 PLUS is intended for use in pregnant women at increased risk for fetal aneuploidy and can be used as early as 10 weeks gestation.
Are you Bullish or Bearish on ?
Sentiment on ()
Thanks for sharing your thoughts.